Рабиа Асле

Научные публикации

• Repurposing of glatiramer acetate to treat cardiac ischemia in rodent models
• Human Gut Microbiota in Cardiovascular Disease
• Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials
• Impact of age over 70 years in the new allocation system on the outcomes of heart transplantation in the US
• Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
• Endomyocardial biopsy in clinical practice: the diagnostic yield and insights from a 5-year single-center experience
• Reversibility of precapillary pulmonary hypertension and outcomes after heart transplantation bridged with left ventricular assist devices: Insight from the United Network for Organ Sharing
• Cardiac magnetic resonance imaging in heart transplant recipients with biopsy-negative graft dysfunction
• Ser194Leu DSG2 mutation, associated with arrhythmogenic left ventricular cardiomyopathy and ventricular tachycardia
• Rejection Requiring Treatment within the First Year following Heart Transplantation: The UNOS Insight
• Inhibition of angiogenesis in the management of refractory gastrointestinal bleeding in patients with LVAD support
• Diurnal cardio-respiratory changes in ambulatory individuals deciphered using a multi-parameter wearable device
• Real-Life Utilization of Criteria Guidelines for Diagnosis of Cardiac Sarcoidosis (CS)
• Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
• Management of Acute Myocarditis and Post-hospitalization Follow-up: A Position Statement from the Israel Heart Society
• Definition and Diagnosis of Acute Myocarditis: A Position Statement of the Israel Heart Society
• Cardiac Transplantation: Physiology and Natural History of the Transplanted Heart
• PET Assessment of Cardiac Allograft Vasculopathy After Heart Transplantation: Beyond Coronary Angiography and IVUS
• Vascular Function in Continuous Flow LVADs: Implications for Clinical Practice
• A second-generation artificial intelligence-based therapeutic regimen improves diuretic resistance in heart failure: Results of a feasibility open-labeled clinical trial
• Advanced Hemodynamic Monitoring Allows Recognition of Early Response Patterns to Diuresis in Congestive Heart Failure Patients
• Giant Intracardiac Lipoma: A Case Report and the Role of Multimodality Cardiac Imaging
• A case series of eosinophilic myocarditis: different faces of the same coin
• A Rare Case of Endocarditis and Mycotic Pseudoaneurysm of the Left Ventricle Caused by Escherichia coli Following Transcatheter Aortic Valve Replacement
• Characteristics, Predictors, and Outcomes of Early mTOR Inhibitor Use After Heart Transplantation: Insights From the UNOS Database
• Evolution of In-Hospital Outcomes Among Left Ventricular Assist Device Recipients
• Characteristics and outcomes of left ventricular assist device recipients transplanted before and after the new donor heart allocation system
• Non-steroidal aldosterone receptor antagonism: a 'fine' treatment for heart failure patients?
• Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination
• Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies
• Post-transplant Lymphoproliferative Disorder Following Cardiac Transplantation
• Management of heart failure with reduced ejection fraction: challenges in patients with atrial fibrillation, renal disease and in the elderly
• Sirolimus-Based Immunosuppression Is Associated with Decreased Incidence of Post-Transplant Lymphoproliferative Disorder after Heart Transplantation: A Double-Center Study
• Outcomes after heart transplantation in patients with cardiac sarcoidosis
• Incidence and long-term outcome of heart transplantation patients who develop postoperative renal failure requiring dialysis
• In Search of Clinical Impact: Advanced Monitoring Technologies in Daily Heart Failure Care
• Persistent sex differences in outcomes after coronary heart disease: time to move from observation to action
• Contemporary Pillars of Heart Failure with Reduced Ejection Fraction Medical Therapy
• Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel
• Incidence, Risk Factors, and Outcomes of Stroke Following Cardiac Transplantation
• Improving Diuretic Response in Heart Failure by Implementing a Patient-Tailored Variability and Chronotherapy-Guided Algorithm
• Predictors of Hypoxemia and Related Adverse Outcomes in Patients Hospitalized with COVID-19: A Double-Center Retrospective Study
• The Reply
• Analysis of Trends and Outcomes of 90 and 180 Day Readmissions After Left Ventricular Assist Device Implantation
• State-of-the-art machine learning improves predictive accuracy of 1-year survival after heart transplantation
• Association of Aspirin Treatment With Cardiac Allograft Vasculopathy Progression and Adverse Outcomes After Heart Transplantation
• Longitudinal trends and outcomes of adult heart transplantation in the U.S
• Novel technologies in the management of heart failure with preserved ejection fraction: a promise during the time of disappointment from pharmacological approaches?
• Dynamics of myocardial fibrosis after left ventricular assist device implantation: should speeding up the scar have us scared stiff?
• Impact of Sirolimus as a Primary Immunosuppressant on Myocardial Fibrosis and Diastolic Function Following Heart Transplantation
• Trends and outcomes of device-related 30-day readmissions after left ventricular assist device implantation
• Sex Differences in Outcomes After Myocardial Infarction in the Community
• Effects of mTOR inhibitor-related proteinuria on progression of cardiac allograft vasculopathy and outcomes among heart transplant recipients
• Maintenance immunosuppression in heart transplantation: insights from network meta-analysis of various immunosuppression regimens
• Coronary Disease Surveillance in the Community: Angiography and Revascularization
• Intravenous bevacizumab as a novel treatment for refractory left ventricular assist device-related gastrointestinal bleeding
• Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses
• Predictors and Clinical Outcomes of Vasoplegia in Patients Bridged to Heart Transplantation With Continuous-Flow Left Ventricular Assist Devices
• Left ventricular assist devices as destination therapy in stage D heart failure
• The Dilemma of Resuming Antithrombotic Therapy After Intracranial Hemorrhage in Patients With Left Ventricular Assist Devices
• Utilization of Percutaneous Mechanical Circulatory Support Devices in Cardiogenic Shock Complicating Acute Myocardial Infarction and High-Risk Percutaneous Coronary Interventions
• Diastolic Pulmonary Gradient as a Predictor of Right Ventricular Failure After Left Ventricular Assist Device Implantation
• Predictors and Outcomes of Renal Replacement Therapy After Left Ventricular Assist Device Implantation
• Incidence of Malignancies in Patients Treated With Sirolimus Following Heart Transplantation
• Management of Patients with Heart Failure: Focus on New Pharmaceutical and Device Options
• Galectin-3 Levels and Outcomes After Myocardial Infarction: A Population-Based Study
• Trends in In-Hospital Mortality, Length of Stay, Nonroutine Discharge, and Cost Among End-Stage Renal Disease Patients on Dialysis Hospitalized With Heart Failure (2001-2014)
• Trends in utilization, mortality, major complications, and cost after total artificial heart implantation in the United States (2009-2015)
• Haptoglobin Phenotype Is Associated With High-Density Lipoprotein-Bound Hemoglobin Content and Coronary Endothelial Dysfunction in Patients With Mild Nonobstructive Coronary Artery Disease
• Cardiovascular risk prediction in older adults with the use of biomarkers
• The Iron-Klotho-VDR Axis Is a Major Determinant of Proximal Convoluted Tubule Injury in Haptoglobin 2-2 Genotype Diabetic Nephropathy Patients and Mice
• Hypercholesterolemia after conversion to sirolimus as primary immunosuppression and cardiac allograft vasculopathy in heart transplant recipients
• Genomewide association study reveals novel genetic loci associated with change in renal function in heart transplant recipients
• Timing of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor initiation and allograft vasculopathy progression and outcomes in heart transplant recipients
• Danazol treatment of gastrointestinal bleeding in left ventricular assist device-supported patients
• Reply: Mammalian Target of Rapamycin Inhibitors and Survival in Heart Transplant Recipients: Miracle or Mirage?
• Hemodynamic Assessment of Patients With and Without Heart Failure Symptoms Supported by a Continuous-Flow Left Ventricular Assist Device
• Uric acid is an independent predictor of cardiac allograft vasculopathy after heart transplantation
• Meta-analysis of the association of the haptoglobin genotype with cardiovascular outcomes and the pharmacogenomic interactions with vitamin E supplementation
• Regional Variation in Mortality, Major Complications, and Cost After Left Ventricular Assist Device Implantation in the United States (2009 to 2014)
• Induction immunosuppressive therapy in cardiac transplantation: a systematic review and meta-analysis
• Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant Recipients
• Therapeutic Approach to Patients with Heart Failure with Reduced Ejection Fraction and End-stage Renal Disease
• The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus
• Impact of Diabetes Mellitus on Outcomes in Patients Supported With Left Ventricular Assist Devices: A Single Institutional 9-Year Experience
• Anti-oxidative treatment with vitamin E improves peripheral vascular function in patients with diabetes mellitus and Haptoglobin 2-2 genotype: A double-blinded cross-over study
• Regional Variation in Mortality, Length of Stay, Cost, and Discharge Disposition Among Patients Admitted for Heart Failure in the United States
• Haptoglobin Genotype as a Determinant of Benefit or Harm From Niacin for Participants With Diabetes
• Effect of vitamin E supplementation on HDL function by haptoglobin genotype in type 1 diabetes: results from the HapE randomized crossover pilot trial
• Pharmacogenomic interaction between the Haptoglobin genotype and vitamin E on atherosclerotic plaque progression and stability
• Haptoglobin genotype-dependent differences in macrophage lysosomal oxidative injury
• Is the Hp 2-2 diabetic mouse model a good model to study diabetic nephropathy?
• Pharmacogenomic application of the haptoglobin genotype in the treatment of HDL dysfunction
• Poor lysosomal membrane integrity in proximal tubule cells of haptoglobin 2-2 genotype mice with diabetes mellitus
• Vitamin E therapy results in a reduction in HDL function in individuals with diabetes and the haptoglobin 2-1 genotype
• Cholesterol efflux capacity and atherosclerosis
• Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype
• Divergent effects of alpha-tocopherol and vitamin C on the generation of dysfunctional HDL associated with diabetes and the Hp 2-2 genotype
• Haptoglobin: basic and clinical aspects
• Pharmacogenomic effect of vitamin E on kidney structure and function in transgenic mice with the haptoglobin 2-2 genotype and diabetes mellitus
• Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype
• Hypothesis--haptoglobin genotype and diabetic nephropathy
• Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to intraplaque hemorrhage and plaque vulnerability
• In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease
• Haptoglobin genotype determines myocardial infarct size in diabetic mice
• Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo
• Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction
• Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo
• Serum chelatable redox-active iron is an independent predictor of mortality after myocardial infarction in individuals with diabetes
• Tyrosine kinases inhibitors block Fas-mediated deleterious effects in normoxic and hypoxic ventricular myocytes
• Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease